Ceralasertib
- Generic Name
- Ceralasertib
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24N6O2S
- CAS Number
- 1352226-88-0
- Unique Ingredient Identifier
- 85RE35306Z
- Background
Ceralasertib is under investigation in clinical trial NCT03682289 (Phase II Trial of AZD6738 Alone and in Combination With Olaparib).
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 194
- Registration Number
- NCT05061134
- Locations
- 🇬🇧
Research Site, Northwood, United Kingdom
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
- Conditions
- Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal CarcinomaAdvanced Endometrial CarcinomaAdvanced Gastric CarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaAdvanced Malignant Solid NeoplasmAdvanced Salivary Gland CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Multigated Acquisition ScanProcedure: Positron Emission Tomography
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT04704661
- Locations
- 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Muhammad Furqan
- Target Recruit Count
- 30
- Registration Number
- NCT04699838
- Locations
- 🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 57
- Registration Number
- NCT04564027
- Locations
- 🇪🇸
Research Site, Madrid, Spain
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 200
- Registration Number
- NCT04550104
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧Belfast City Hospital, Belfast, United Kingdom
🇬🇧Freeman Hospital, Newcastle upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom
Olaparib with Ceralasertib in Recurrent Osteosarcoma
- Conditions
- Osteosarcoma RecurrentOsteosarcoma
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 63
- Registration Number
- NCT04417062
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital; UCSF Pediatrics Hematology Oncology, San Francisco, California, United States
🇺🇸Dana Farber Cancer Institite, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering, New York, New York, United States
AZD6738 Plus Durvalumab in Biliary Tract Cancer
- Conditions
- Chemotherapy EffectBile Duct Cancer
- Interventions
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT04298008
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
- Conditions
- Chemotherapy EffectBile Duct Cancer
- Interventions
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 74
- Registration Number
- NCT04298021
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT04239014
- Locations
- 🇪🇸
Research Site, Barcelona, Spain
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
- Conditions
- Anatomic Stage IIIA Breast Cancer AJCC v8Germline BRCA1 Gene MutationGermline BRCA2 Gene MutationHER2/Neu NegativeMetastatic Breast CarcinomaPrognostic Stage III Breast Cancer AJCC v8Advanced Breast CarcinomaAnatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04090567
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.